Completed PHASE3 INTERVENTIONAL 2-arm NCT03475225

Vitamine D in Drug Resistant Epilepsy (EPI-D)

Effect of the Treatment of Vitamin D Deficiency in Drug-resistant Epilepsy

Sponsor: APHP

Interventions Cholecalciferol Placebo Oral

Updated 7 times since 2018 Last updated: Jul 10, 2024 Started: Apr 3, 2018 Primary completion: Mar 4, 2020 Completion: Dec 9, 2020

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Drug Resistant Epilepsy, this trial is completed. The trial is conducted by APHP and has accumulated 7 data snapshots since 2018. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Aug 2024 — Sep 2024 [monthly]

Completed PHASE3

Status: Unknown → Completed
Jul 2024 — Aug 2024 [monthly]

Unknown PHASE3

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE3
May 2020 — Jan 2021 [monthly]

Unknown Status PHASE3

Status: Not Yet Recruiting → Unknown Status

▶ Show 2 earlier versions

Jun 2018 — May 2020 [monthly]

Not Yet Recruiting PHASE3
Apr 2018 — Jun 2018 [monthly]

Not Yet Recruiting PHASE3

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

APHP
Centre Hospitalier St Anne
FFRE
LFCE

Data source: Centre Hospitalier St Anne

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Le Kremlin-Bicêtre, France
• Paris, France